Simcha Therapeutics Announces Agreement to Develop IL-18
Simcha Therapeutics Announces its Scientific Advisory Board, Comprised of Renowned Experts in Immunology and Oncology
Simcha Therapeutics closed a $40 million Series B and has begun dosing patients in a Phase I/II trial for its lead program, the biotech announced. The raise should take Simcha into 2024 and help complete the just-launched Phase I portion, a Phase II monotherapy study and a Phase Ib combination trial with a checkpoint inhibitor, founder Aaron Ring told Endpoints News.
NEW HAVEN, Conn., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, today announced the closing of a $40 million Series B financing. The round was led by SR One Capital Management and joined by other new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital. In conjunction with the financing, Simeon George, MD, Chief Executive Officer of SR One Capital Management, has joined the Simcha Therapeutics Board of Directors.